aazxb4z6

Property	Value
?:abstract	Covid-19 has affected 16Millions people worldwide with 644K death as of July 26th, 2020. It is associated with inflammation and microvascular thrombosis—anticoagulation in widely used in these patients especially in patients with elevated D-Dimers. The significance of anticoagulation in these patients is not yet established. We aim to define the anticoagulation pattern and its impact on outcomes (28-day survival, LOSICU, DVT, and PE and bleeding complications. We also observe if levels of D-Dimers affect the anticoagulation prescription. Methods: We analyzed data of all consecutive patients with Covid-19 ARDS admitted to ICU retrospectively. The primary variable of interest was anticoagulation. The daily dose of anticoagulant medication for each patient was recorded. Survival (28-day survival), Length of stay in ICU (LOSICU), the occurrence of DVT, PE, or bleeding were primary outcome variables. We also recorded confounding factors with potential impact on clinical outcomes. We assign Patients to one of the four groups based on anticoagulant dosing during the ICU (increasing dose, decreasing dose, increase followed by a decrease, multiple changes). We analyze the effect of different anticoagulation dosing strategies on 28-day survival, LOSICU, the occurrence of DVT, PE, and bleeding. We also observe if levels of D-Dimers affect the anticoagulation prescription. Results: The sample includes 149 patients. The most frequently used medication was subcutaneous Enoxaparin (85.2%). The Enoxaparin mean dose per day for the whole sample was 49.5mg + 15.7 (mean + SD). There was no significant difference in doses of anticoagulants between survivors and nonsurvivors (62.8 mg + 21.7 mg vs. 61.2 mg + 25.7mg, p 0.3). Multinomial regression showed no difference in 28-day survival among four-dose modification (increasing dose, decreasing dose, increase followed by a decrease, multiple changes). Logistic regression showed that BMI, D-Dimers, platelets, and the use of mechanical ventilation predict 28-day survival. Kaplan-Meier Survival plots for 4 anticoagulant groups showed no survival advantage for any anticoagulant strategy. Secondary outcome analysis showed that d-dimer levels significantly affect anticoagulants doses. Conclusion: Prescription of anticoagulation is quite variable in patients admitted to ICU for Covid-19 associated ARDS. Anticoagulation dosing strategy has no significant effect on 28-day survival, LOSICU, the occurrence of DVT, PE, or bleeding.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C0003280> <https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C0019080> <https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C0021368> <https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C0027627> <https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C0040053> <https://research.tib.eu/covid-19/entity/aazxb4z6_hasAnnotation_C1825598>
?:creator	<https://research.tib.eu/covid-19/entity/Nadeem%2C_Rashid%3B_Thomas%2C_Stelvie_John%3B_Fathima%2C_Zoubia%3B_Palathinkal%2C_Anju_Subin%3B_Alkilani%2C_Yazan_Emad%3B_Dejan%2C_Efaf_Ahmad%3B_Darwish%2C_Ismail_mohammad_ismail%3B_Alsubousi%2C_Aisha_Ali%3B_Backour%2C_Alaa_Marouf%3B_Kandeel%2C_Hussein%3B_Omar%2C_Mohamad%3B_Kewan%2C_Hesham_Fawzy_Yehia_Taha%3B_makhlof%2C_Mahmod_Elshahat%3B_Kotgire%2C_Anand_Bhaskarrao>
?:doi	10.1016/j.hrtlng.2020.10.009
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.hrtlng.2020.10.009>
?:journal	Heart_Lung
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/5549f7ea1321a7a58908899aa58b4d62c2e66adf.json
?:pmc_json_files	document_parses/pmc_json/PMC7574696.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7574696>
?:pmid	<https://research.tib.eu/covid-19/entity/33138975.0>
?:pmid	33138975.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/aazxb4z6_HAS_C0060323_INTERACTS_WITH_C0003280>
?:sha_id	<https://research.tib.eu/covid-19/entity/5549f7ea1321a7a58908899aa58b4d62c2e66adf>
?:source	Elsevier; Medline; PMC
?:title	Pattern of anticoagulation prescription for patients with Covid-19 Acute Respiratory Distress Syndrome admitted to ICU. Does it impact outcome?
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-20

Property

Value

?:abstract

Covid-19 has affected 16Millions people worldwide with 644K death as of July 26th, 2020. It is associated with inflammation and microvascular thrombosis—anticoagulation in widely used in these patients especially in patients with elevated D-Dimers. The significance of anticoagulation in these patients is not yet established. We aim to define the anticoagulation pattern and its impact on outcomes (28-day survival, LOSICU, DVT, and PE and bleeding complications. We also observe if levels of D-Dimers affect the anticoagulation prescription. Methods: We analyzed data of all consecutive patients with Covid-19 ARDS admitted to ICU retrospectively. The primary variable of interest was anticoagulation. The daily dose of anticoagulant medication for each patient was recorded. Survival (28-day survival), Length of stay in ICU (LOSICU), the occurrence of DVT, PE, or bleeding were primary outcome variables. We also recorded confounding factors with potential impact on clinical outcomes. We assign Patients to one of the four groups based on anticoagulant dosing during the ICU (increasing dose, decreasing dose, increase followed by a decrease, multiple changes). We analyze the effect of different anticoagulation dosing strategies on 28-day survival, LOSICU, the occurrence of DVT, PE, and bleeding. We also observe if levels of D-Dimers affect the anticoagulation prescription. Results: The sample includes 149 patients. The most frequently used medication was subcutaneous Enoxaparin (85.2%). The Enoxaparin mean dose per day for the whole sample was 49.5mg + 15.7 (mean + SD). There was no significant difference in doses of anticoagulants between survivors and nonsurvivors (62.8 mg + 21.7 mg vs. 61.2 mg + 25.7mg, p 0.3). Multinomial regression showed no difference in 28-day survival among four-dose modification (increasing dose, decreasing dose, increase followed by a decrease, multiple changes). Logistic regression showed that BMI, D-Dimers, platelets, and the use of mechanical ventilation predict 28-day survival. Kaplan-Meier Survival plots for 4 anticoagulant groups showed no survival advantage for any anticoagulant strategy. Secondary outcome analysis showed that d-dimer levels significantly affect anticoagulants doses. Conclusion: Prescription of anticoagulation is quite variable in patients admitted to ICU for Covid-19 associated ARDS. Anticoagulation dosing strategy has no significant effect on 28-day survival, LOSICU, the occurrence of DVT, PE, or bleeding.

is ?:annotates of